Company ProfilePremium

Jinhai Medical Technology Limited (formerly Jinhai International Group Holdings Limited)

Company Profile Analysis

Ticker: 2225.HK今海醫療科技股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jinhai Medical Technology Limited - Company showcase

Year Founded & Workforce

2006

472 Employees

Jinhai Medical Technology Limited logo

Jinhai Medical Technology Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jinhai Medical Technology Limited Overview

Jinhai Medical Technology is a small-cap, Hong Kong-listed holding company in the late stage of a pivot from a Singapore construction-labour supplier into a Shanghai-based distributor and solutions provider of minimally invasive surgery (MIS) products. The legacy business, founded in 2006 as Kakiko, supplies foreign construction workers, operates workers' dormitories and provides small IT and construction-ancillary services in Singapore. Since Shanghai real-estate entrepreneur Chen Guobao acquired control in 2019, the group has built a PRC medical-device business that grew from S$0.7 million of revenue in FY2022 to S$30.0 million in FY2025 and S$25.4 million in 1H2026 alone, now 75% of group revenue. Its most visible technology claim is a navigated spinal endoscopy technique co-launched with Medtronic China in late 2025. The group remains loss-making, highly customer-concentrated and thinly margined, yet trades at a market value of roughly HK$22.5 billion, more than 50 times trailing sales.


What the company does

The group reports two operating "natures" plus a corporate cost centre. The CODM (the executive directors) reviews revenue by nature and profit or loss for the group as a whole, so the group presents only entity-wide IFRS 8 disclosures: "Products", "Services" and "Others" (FY2025 results, Note 3).

  1. Products (PRC): provision of minimally invasive surgery solutions and medical products and the related service fee. Revenue is recognised at a point in time. It is earned through Shanghai Jinhai Medical Technology Company Limited (上海今海醫療科技有限公司) and related PRC subsidiaries, including Jinhai Technology Development (Shanghai) Co., Ltd. and, from January 2026, the 51%-owned Jinhai Biomedical Technology (Shanghai) Co., Ltd.

  2. Services (mainly Singapore): manpower outsourcing and ancillary services to building and construction contractors; workers' dormitory services, accounted for as rental income; IT services (historically to a single customer); and construction ancillary services (warehousing, cleaning and building maintenance). The 2025 Annual Report's Report of the Directors also mentions manpower outsourcing in China, and the FY2025 geographic split shows a small amount of PRC service revenue, but this is immaterial.

  3. Others: corporate office functions (Hong Kong and holding-company costs, including the large equity-settled share-based payment charges since 2024).

The company's own description (paraphrased from the latest filings)

In the 2025 Annual Report, management says it has reassessed strategic direction and resolved to allocate group resources to MIS solutions, medical products and related services. It frames China's MIS-device market as among the fastest growing globally. The company states it will compete by (a) strengthening R&D, (b) expanding its distribution network, (c) developing new products and (d) promoting resource integration. In the same report, management expects the Singapore labour-dispatch, dormitory and construction-related businesses to be materially affected as the Singapore Government reorients investment priorities from infrastructure towards AI. In the 1H2026 interim announcement it says it will review the market position and prospects of the Singapore manpower business in 2H2026.

Revenue model and mix

Revenue type (FY2025)RecognitionSGD K% of total
Product sales: MIS solutions and medical products and related service fee (PRC)Point in time29,96464.7
Service: manpower outsourcing and ancillary servicesOver time12,68527.4
Rental: dormitory services (Singapore)Lease income2,9236.3
Service: IT servicesOver time4340.9
Service: construction ancillary servicesOver time2700.6
Total—46,276100.0

Source: FY2025 annual results announcement, Note 3 and MD&A.

In 1H2026 the product line rose to S$25.4 million of S$34.0 million (74.7%). The model is therefore now predominantly product sales, with no disclosed subscription or licensing revenue. The product revenue line includes a "related service fee", but the split between hardware/consumable sales and service fees is not publicly disclosed.

Value-chain position: independent characterisation

The financial signature of the medical business points to a distribution and commercialisation model rather than a vertically integrated manufacturer:

Thin product margins: "Cost of inventories sold" relative to product revenue implies low gross margins: about 5.1% in FY2023 (19,390 vs 20,431), 4.5% in FY2024 (24,768 vs 25,927), 12.7% in FY2025 (26,162 vs 29,964) and 15.4% in 1H2026 (21,519 vs 25,427). This is an analyst approximation; inventory cost may not equal the full cost of product sales.

Minimal R&D: R&D expenditure was only S$850k in FY2024, S$742k in FY2025 and S$112k in 1H2026, against product revenue in the tens of millions.

Extreme customer concentration: In FY2024 a single customer ("Customer B") contributed S$24.2 million, 93% of product revenue. In 1H2026 two customers contributed S$25.0 million, 98% of product revenue. These patterns are consistent with sales to a small number of distributors or platform partners rather than to many hospitals directly.

Commercial build-out: A Chief Marketing Officer (Mr. Ma Chengdong) was appointed on 3 August 2026, with responsibility for marketing strategy, market access, academic promotion, sales and channel operations, and the commercialisation of the group's medical device and equipment products (voluntary announcement, 3 August 2026).

Technology partnership with Medtronic: In November 2025 the subsidiary co-launched a navigated spinal endoscope technique with Medtronic China's Orthopedics and Neurosurgery Business Group. On 6 November 2025 Jinhai Technology Development (Shanghai) signed a strategic cooperation framework agreement with Medtronic Changzhou Medical Device Co., Ltd. to promote real-time navigation and tracking spinal endoscopy in Chinese clinical practice (AR2025, Chairman's Statement). This positions Jinhai as a clinical-technique and channel partner adjacent to a global OEM.

In the Singapore legacy business, Jinhai is a labour intermediary (deploying foreign workers to contractors, paid by deployment hours, with salespeople commissioned on hours deployed) and a landlord of purpose-built workers' accommodation. Those properties are now pledged as security for group borrowings.

Customer types and end-markets

BusinessCustomer typeEnd-market
MIS solutions and medical productsNot named. Two customers (A and B) accounted for 55.3% of group revenue in FY2025 and 73.6% in 1H2026PRC hospital surgical market (spine and broader MIS); end-users are surgeons and hospitals
Manpower outsourcingBuilding and construction contractors in SingaporeSingapore construction
Dormitory servicesEmployers of foreign workersSingapore foreign-worker accommodation
IT servicesHistorically a sole IT customer (FY2022 and FY2023 MD&A)—
Construction ancillaryContractors and industrial tenantsSingapore construction and industrial property

Strategy

Stated strategy (themes from AR2025 and the 1H2026 interim)

  1. Medical focus. Resources are to be allocated to MIS solutions, medical products and related services, which the board sees as the long-term growth driver.

  2. Four competitive levers. (a) R&D capability, (b) distribution-network expansion, (c) new product development, (d) resource integration.

  3. Healthcare M&A. Net proceeds of the August 2025 subscription are earmarked HK$96.6m for M&A of healthcare projects or companies and investment in healthcare industries, HK$32.2m for R&D and HK$32.2m for working capital, all targeted for use by December 2026.

  4. Singapore review. Management expects the Singapore construction-linked businesses to be materially affected by the government's pivot to AI. The board will review the manpower business's market position in 2H2026, and the remaining HK$1.9m of IPO proceeds for lorries keeps being deferred.

  5. Asia-Pacific expansion. A long-standing aim to extend existing businesses into the Asia-Pacific region, including China, and to add value-added labour services (skills training, quality improvement).

  6. Cost discipline. Management is preserving cash through stricter cost controls amid geopolitical, trade-war and oil-crisis risks flagged for 2026.

Strategic initiatives in the last 24 months

DateInitiativeTypeDetail / targetSource
Jan 2024Singapore dormitory acquisitionAsset investmentS$10.2mFY2023 results
9 Jan 2024Performance-linked option grant to medical leadershipTalent / incentive128.6m pre-split options at HK$2.54 (514.4m post-split at HK$0.635), vesting 20/30/50% on 30 Apr 2025, 2026 and 2027 subject to performance targetsFY2025 results
12 Dec 20241:4 share subdivisionCapital marketsTo improve trading liquidity (rationale per circular of 22 Nov 2024)FY2025 results
Aug 2025HK$162m equity raise from the Li familyFundingHealthcare M&A, R&D, working capitalFY2025 results
Sep 2025Re-hiring of CFO Wong Man YiuLeadershipFinance, tax, treasury, IR, corporate financeMarketScreener
Nov 2025Navigated spinal endoscopy launch with Medtronic China (CIIE)Product / partnershipSpine surgery precision and adoptionAR2025
6 Nov 2025Medtronic Changzhou strategic cooperation frameworkPartnershipPromote real-time navigation and tracking spinal endoscopy in Chinese clinical practiceAR2025
23 Jan / 25 Feb 2026Jinhai Biomedical JV and RMB20m capital increaseNew businessMedical products; 51:49 with Li family vehicleFY2025 results
3 Aug 2026CMO appointmentCommercial build-outMarket access, academic promotion, channelsAnnouncement
1H2026Capital project prepaymentsCapexS$2.85m PPE prepayment and S$3.6m prepayment to contractor (purpose not disclosed)1H2026 results

ESG commitments. The group operates an environmental management system focused on electricity and water conservation, and reports no environmental non-compliance in FY2025 (AR2025 Directors' Report). It has published no quantitative emissions targets.

Medium-term financial targets or guidance. None publicly disclosed. Management offers only qualitative expectations, for example that medical sales will continue to grow in 2H2026.

Products & Services

The company publishes very little product-level detail in its HKEX filings. The catalogue below lists everything disclosed. Specifications, pricing and SKUs not stated in filings are marked accordingly.

Products segment (PRC)

OfferingDescriptionKey specs/capabilitiesTarget customerLaunch/versionPricing modelSource
Minimally invasive surgery solutionsIntegrated MIS solution sales with a related service fee—PRC hospitals, via a small number of large customersBusiness started 2019; material revenue from FY2023Point-in-time product sale plus related service fee; price points not disclosedFY2023 and FY2025 results
Medical products / medical equipmentSale of medical equipment and consumables (management uses "medical equipment" and "medical products" interchangeably)—PRC healthcare providers and distributors2019 onward—FY2025 MD&A
Navigated (real-time navigation and tracking) spinal endoscopy techniqueTechnique jointly launched with Medtronic China's Orthopedics & Neurosurgery Business Group at the 8th CIIE, November 2025; intended for spine surgeryManagement says it should improve precision and intelligence in spinal surgery, shorten clinicians' learning curve for spinal endoscopy, and broaden clinical application. Device-level specifications and regulatory registration status not disclosedSpine surgeons and hospitals in ChinaLaunched Nov 2025; framework agreement with Medtronic Changzhou, 6 Nov 2025—AR2025 Chairman's Statement
Jinhai Biomedical product platformNew 51%-owned subsidiary focused on medical products; registered capital RMB25m after Feb 2026 increaseProduct scope not disclosed—Established 23 Jan 2026—FY2025 results; 1H2026 results

Flagship brands, trademarks or NMPA product registrations are not publicly disclosed in the filings reviewed. The co-chairman's background as founder of Shanghai Anbaida (in-vitro diagnostic reagent sales) and as a first-tier distributor of Roche Diagnostics in Shanghai since 2004 suggests IVD distribution could become a future adjacency. This is an analyst inference and is not stated in company guidance.

Services segment (Singapore)

OfferingDescriptionSpecs/capabilitiesTarget customerSincePricing modelSource
Manpower outsourcing and ancillary servicesDeployment of foreign construction workers to contractors' projects, with ancillary servicesWorkforce of several hundred including foreign workers (472 total group employees at 30 Jun 2026); foreign worker levy S$2.9m in FY2025Building and construction contractors2,006Revenue recognised over time; sales commissions tied to hours of deployment, implying hourly or deployment-based billingFY2025 results
Dormitory servicesWorkers' dormitories; investment properties carried at S$18.2m (30 Jun 2026), pledged for borrowingsOne dormitory acquired Jan 2024 (S$10.2m); one ceased operation Oct 2024. Total bed count not disclosedEmployers of foreign workersPre-IPORental income (IFRS 16)FY2023 and FY2025 results
IT servicesMaintenance and support days for a sole IT customer—Single customerPre-2021Over-time service fee by support daysFY2022 and FY2023 MD&A
Construction ancillary servicesWarehousing, cleaning, building maintenanceWarehousing revenue fell with less industrial space rented outContractors and industrial occupiersPre-IPOOver timeFY2022 and FY2023 MD&A
Value-added labour services (proposed)Skills training and quality improvement for labour forcesProposal onlyContractorsNot launched—AR2025

Financial Narrative

Methodology: EBIT is defined as profit before tax plus finance costs. EBITDA is EBIT plus depreciation of PPE, right-of-use assets and investment properties. Net income is "profit/(loss) for the year" (total); "attributable" is to owners of the company. Ratios are analyst calculations from filed figures.

Income statement: notes and sources

Sources: FY2022 results (FY2021 restated, FY2022); FY2023 results; FY2025 results (FY2024, FY2025). FY2021–FY2023 share-based payment shown as 0 because the option scheme was adopted only on 29 December 2023. Aggregator check: TipRanks EBITDA matches for FY2021–FY2023 (S$5.44m, S$5.25m, S$1.11m) but shows S$-16.82m for FY2024 against the -12.44m computed here, a definitional discrepancy that is noted.

Margins and growth

Revenue CAGR FY2021–FY2025: approx. 20.6% per year (21.9m to 46.3m). FY2021 YoY growth is against FY2020 revenue of S$22.47m (TipRanks; the restated basis may differ). Longer-run context from TipRanks (aggregator): revenue was S$45.05m (FY2016), S$44.44m (FY2017), S$47.46m (FY2018) and S$51.90m (FY2019) before falling to S$22.47m in FY2020 during Singapore's COVID-19 dormitory lockdowns and construction stoppage. On this longer view, FY2025 group revenue is still below pre-pandemic levels.

Interim snapshot and trailing twelve months: notes and sources

Source: 1H2026 results. TTM equals FY2025 minus 1H2025 plus 1H2026. Excluding share-based payments, the 1H2026 loss for the period would have been roughly S$0.4 million (analyst calculation). Non-controlling interests earned a profit of S$732k in 1H2026, consistent with profitable activity inside the newly formed 51%-owned Jinhai Biomedical.

Balance sheet

At 30 June 2026 (1H2026 results):

  • Total assets S$100.3m; bank and cash S$18.2m plus time deposits S$10.5m (S$28.7m in total).

  • Trade receivables S$25.9m; trade payables S$23.4m; inventories S$3.3m.

  • Borrowings S$11.9m; lease liabilities S$2.3m.

  • Total equity S$55.7m, of which non-controlling interests S$3.8m; net current assets S$31.0m.

  • New items: a S$2.85m prepayment for PPE and a S$3.6m prepayment to a contractor, which point to a capital project. Its nature is not disclosed.

FY2022 cash excludes a S$968k fixed deposit. FY2023 goodwill is shown as 0 because no goodwill line appeared on the FY2023 balance sheet, while goodwill of S$522k is carried from FY2024.

Cash flow

The company disclosed FY2025 PPE capex of S$0.1m (FY2024: S$1.0m) and gross equity proceeds of S$26.6m from the August 2025 subscription, and stated no buybacks in any period. FY2023 financing inflow reflects the October 2023 placing (S$17.47m gross).

Ratios

Notes: Debt/equity matches the company's reported gearing ratio for FY2021–FY2025. Net debt/EBITDA for FY2024 and FY2025 is mechanically computed but not meaningful because EBITDA was negative. Receivable and payable days use year-end balances against revenue and cost of sales. Inventory days use cost of inventories sold where disclosed (FY2023–FY2025) and cost of sales otherwise.

Commentary on trends, inflections and drivers

Revenue. The five-year record has three phases. FY2021–FY2022 was a COVID-depressed Singapore services business at roughly S$22m. FY2023 saw revenue double to S$45.6m as the PRC medical business scaled to S$20.4m and dormitory rents surged. FY2024–FY2025 brought a plateau and then a decline at group level (S$50.2m, then S$46.3m) as Singapore dormitory income collapsed, partly masking continued medical growth (+26.9%, then +15.6%). The 1H2026 print of S$34.0m, up 134% YoY, is the first clear sign that medical growth now dominates the group trajectory. TTM revenue reached a record S$65.8m.

Gross margin. The steady compression from 45.4% (FY2022) to 15.5% (FY2025) is a mix effect. High-margin rental and labour revenue was replaced by low-margin product sales, and the FY2023 MD&A explicitly cites the low margin of the MIS business. The partial recovery to 19.5% in 1H2026 coincides with better implied product margins (about 15% vs about 5% in FY2023–FY2024) and a rebound in Singapore dormitory rental rates.

Operating losses. The FY2024–FY2025 losses (about S$18m and S$17m) are heavily distorted by non-cash share-based payments of S$13.2m and S$9.1m from the January 2024 option grant. Underlying EBITDA excluding these charges was approximately break-even in FY2024 (+S$0.7m) and modestly negative in FY2025 (−S$2.8m). The FY2023 admin step-up (+S$5.7m) reflected promotional and marketing spend, hiring of industry veterans and leased R&D space for the medical business.

Balance sheet. The group was net cash in four of five year-ends. Equity has been replenished twice by placements to insiders and associates: S$17.5m in October 2023 and S$26.6m in August 2025. These placements, not internal cash generation, have funded accumulated losses. Borrowings (S$12.0m at end-FY2025) are short-term, secured on the Singapore dormitories, and partly comprise loans from the parent company for daily operations (FY2025 MD&A). The group reported no unutilised banking facilities at end-FY2025 or at 30 June 2026.

Working capital. The jump in receivable days to 121 at end-FY2025 and payables to 153 days reflects large, back-end-loaded product sales to concentrated customers, financed by extended supplier credit. Trade payables over 90 days rose from S$0.1m (FY2024) to S$5.9m (FY2025) and S$8.0m (1H2026). This is a key monitorable for cash-flow quality.

Returns. ROE, ROA and ROIC have been negative since FY2023 and are unlikely to turn positive before share-based payment charges taper. The third and largest option tranche (50%) vests on 30 April 2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment

MetricFY2021FY2022FY2023FY2024FY2025

Products revenue (SGD K)

1,55865620,43125,92729,964

Services revenue (SGD K)

20,33821,62425,21324,31416,312

Total revenue (SGD K)

21,89622,28045,64450,24146,276

Products profit before tax (SGD K)

-754-704-2,178-3,645-2,088

Services profit before tax (SGD K)

2,8173,9161,9121,700-3,514

Others/corporate profit before tax (SGD K)

-2,126-2,428-2,951-16,282-11,560

Group profit before tax (SGD K)

-62784-3,217-18,227-17,162

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2021FY2022FY2023FY2024FY2025

Products PBT margin (%)

-48.4-107.3-10.7-14.1-7.0

Services PBT margin (%)

13.918.17.67.0-21.5

Products revenue YoY growth (%)

0-57.93,014.526.915.6

Services revenue YoY growth (%)

06.316.6-3.6-32.9

Products share of group revenue (%)

7.12.944.851.664.7

Services share of group revenue (%)

92.997.155.248.435.3

Business Lines

Business lineFY2021FY2022FY2023FY2024FY2025

MIS solutions and medical products and service fee (SGD K)

1,55865620,43125,92729,964

Manpower outsourcing and ancillary services (SGD K)

14,30715,01815,75015,11612,685

Dormitory services (SGD K)

4,7895,7878,6158,4192,923

IT services (SGD K)

567417476500434

Construction ancillary services (SGD K)

674402372279270

Business line YoY growth (%)

Business line YoY growth (%)FY2022FY2023FY2024FY2025

MIS and medical products YoY (%)

-57.93,016.626.915.6

Manpower outsourcing YoY (%)

5.04.9-4.0-16.1

Dormitory services YoY (%)

20.848.9-2.3-65.3

IT services YoY (%)

-26.414.15.0-13.2

Construction ancillary YoY (%)

-40.4-7.5-25.0-3.2

Revenue by Segment

Metric1H20242H20241H20252H20251H2026

MIS and medical products revenue (SGD K)

12,30213,6256,33323,63125,427

Manpower outsourcing revenue (SGD K)

006,4516,2346,372

Dormitory revenue (SGD K)

001,3781,5451,909

Group revenue (SGD K)

25,93724,30414,52931,74734,021

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (SGD K)

21,89622,28045,64450,24146,276

Cost of sales and services (SGD K)

14,16912,16433,61538,76439,087

Gross profit (SGD K)

7,72710,11612,02911,4777,189

Administrative expenses (SGD K)

8,69710,24215,94131,94224,463

of which equity-settled share-based payments (SGD K)

00013,1529,119

Depreciation, all categories (SGD K)

5,3654,3874,1025,0194,618

EBIT (SGD K)

70869-2,996-17,454-16,487

EBITDA (SGD K)

5,4355,2561,106-12,435-11,869

EBITDA excluding share-based payments (SGD K)

5,4355,2561,106717-2,750

Finance costs (SGD K)

13285221773675

Profit before tax (SGD K)

-62784-3,217-18,227-17,162

Income tax expense (SGD K)

43566889528233

Net income, total (SGD K)

-498116-4,112-18,255-17,395

Net income attributable to owners (SGD K)

-246468-3,141-17,965-17,080

Basic and diluted EPS as reported (S$ cents)

-0.020.04-0.25-0.35-0.33

Basic EPS adjusted for Dec 2024 1:4 subdivision (S$ cents)

-0.0050.010-0.063-0.35-0.33

Dividends per share (S$ cents)

00000

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin (%)

35.345.426.422.815.5

EBIT margin (%)

0.33.9-6.6-34.7-35.6

EBITDA margin (%)

24.823.62.4-24.8-25.6

Net margin, total (%)

-2.30.5-9.0-36.3-37.6

Revenue YoY growth (%)

-2.61.8104.910.1-7.9

Margin Analysis (%) and Per-Share Data

Metric1H20251H2026TTM to Jun 2026

Revenue

14,52934,02165,768

Gross profit

2,0826,62211,729

Gross margin (%)

14.319.517.8

Administrative expenses

12,5059,95921,917

Share-based payments

5,2703,2307,079

Loss before tax

-10,722-2,997-9,437

Loss for the period

-10,800-3,630-10,225

Loss attributable to owners

-10,253-4,362-11,189

Basic loss per share (S$ cents)

-0.20-0.08—

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (SGD K)

33,76940,27262,22058,86788,834

Cash and bank balances (SGD K)

16,25715,38520,19610,44635,588

Investment properties (SGD K)

1,0091,08212,51221,30818,753

Inventories (SGD K)

8749592,0972,7693,004

Trade receivables (SGD K)

1,4652,2125,5314,85615,384

Listed investments at FVTPL (SGD K)

8,7367,5926,5644,4791,193

Short-term debt incl. current leases (SGD K)

1,6142,7686,60311,79113,051

Long-term debt incl. non-current leases (SGD K)

2541,6813,4782,7311,857

Total debt incl. leases (SGD K)

1,8684,45010,08114,52214,908

Net debt (debt minus cash; negative = net cash) (SGD K)

-14,389-10,935-10,1154,076-20,680

Total equity (SGD K)

24,02424,59237,49032,77951,962

Equity attributable to owners (SGD K)

24,27524,36837,47431,80651,288

Goodwill and intangibles (SGD K)

000522522

Working capital (net current assets) (SGD K)

21,24219,30321,4306,80729,419

Trade payables (SGD K)

2644775,4625,12916,400

Cash Flow

MetricFY2020FY2021FY2022FY2023FY2024

Operating cash flow (SGD Mn)

7.383.344.24-1.91-3.25

Capital expenditure, implied (SGD Mn)

0.130.611.181.241.01

Free cash flow (SGD Mn)

7.252.733.06-3.15-4.26

Investing cash flow (SGD Mn)

-6.04-2.64-1.15-6.51-9.22

Financing cash flow (SGD Mn)

-4.15-4.81-3.7213.622.93

Dividends paid (SGD Mn)

00000

Share buybacks (SGD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, attributable NI / average attributable equity (%)

-1.01.9-10.2-51.9-41.1

ROA, total NI / average total assets (%)

-1.40.3-8.0-30.2-23.6

ROIC, after-tax EBIT / (equity + debt − cash) (%)

-3.81.5-14.2-47.4-52.7

Current ratio (x)

3.242.382.011.291.84

Debt (incl. leases) / equity (%)

7.818.126.944.328.7

Net debt / EBITDA (x; not meaningful when EBITDA ≤ 0)

-2.65-2.08-9.15-0.331.74

Interest coverage, EBIT / finance costs (x)

0.510.2-13.6-22.6-24.4

Asset turnover (x)

0.600.600.890.830.63

Receivable days

24364435121

Inventory days

2329394142

Payable days

7145948153

Cash conversion cycle (days)

4051242810

Revenue by Region

RegionFY2021FY2022FY2023FY2024FY2025

PRC / Mainland China revenue (SGD K)

1,55865620,43125,92729,989

Singapore revenue incl. dormitory rental (SGD K)

20,33821,62425,21324,31416,287

Total (SGD K)

21,89622,28045,64450,24146,276

Region growth and share (%)

Region growth and share (%)FY2022FY2023FY2024FY2025

PRC YoY growth (%)

-57.93,014.526.915.7

Singapore YoY growth (%)

6.316.6-3.6-33.0

PRC share of revenue (%)

2.944.851.664.8

Singapore share of revenue (%)

97.155.248.435.2

Segment Overview

SegmentPRCSingaporeHong KongTotal

Products (MIS and medical)

29,9640029,964

Services (manpower, IT, construction ancillary)

2513,364013,389

Dormitory rental

02,92302,923

Total

29,98916,287046,276

Locations

LocationFY2022FY2023FY202530 Jun 2026

Singapore (SGD K)

1,28213,38719,64019,324

Mainland China (SGD K)

5,0594,1923,0655,416

Hong Kong (SGD K)

4681,3621,146840

Share Price

MetricOct2017Jul2019Mar2021Jul2021Sep2023Jan2024Jul2025Apr2026Jun2026Aug2026Oct2026

Split-adjusted share price (HKD)

0.1300.1020.3830.7850.4980.6351.6404.5303.3304.9354.250

Margin Analysis (%) (Approx. 5-year (vs Jul 2021)–Approx. 1-year (vs Jul 2025))

MetricApprox. 1-year (vs Jul 2025)Approx. 3-year (vs Sep 2023)Approx. 5-year (vs Jul 2021)

Share price change (%)

159754441

Valuation Snapshot

MetricValue

Market capitalisation (HKD Mn)

22,521

Market capitalisation (SGD Mn)

3,702

Enterprise value (SGD Mn), market cap + debt S$14.2m − cash and deposits S$28.7m

3,688

TTM revenue to Jun 2026 (SGD Mn)

65.8

EV / TTM sales (x)

56.1

Price / book, equity attributable at 30 Jun 2026 of S$52.0m (x)

71.2

P/E (x)

Not meaningful (loss-making)

EV / EBITDA (x)

Not meaningful (negative EBITDA)

Capital Markets

ItemStatus

Analyst consensus

No identifiable broker coverage. TipRanks displayed a single "Hold" rating with a HK$0.50 target in mid-2025; source and methodology unclear, so low reliability

Dividend history

No dividends declared or paid FY2021–1H2026; no fixed payout ratio. Board cites losses and cash retention (AR2025 dividend policy)

Buybacks

None executed. AGM (15 Jun 2026) granted a 10% repurchase mandate (about 529m shares)

Issue mandate

20% general mandate (about 1.06bn shares)

Credit ratings (Moody's / S&P / Fitch)

None; unrated

Debt maturity profile at 30 Jun 2026

Borrowings S$11.9m, all current and secured on Singapore investment properties (S$18.2m); lease liabilities S$0.9m current and S$1.4m non-current; no unutilised bank facilities

Analyst Conclusions

Management guidance

There are no numerical targets. Management:

  • Expects medical sales to continue to grow in 2H2026 and is prepared to expand medical product operations in China.

  • Will review the Singapore manpower business in 2H2026.

  • Expects 2H2026 to be economically challenging and continues stringent cost controls.

  • Intends to deploy the HK$146.3m of unutilised August 2025 proceeds (M&A, R&D, working capital) by the end of December 2026.

(1H2026 results.)

Consensus

No formal consensus exists. The only visible third-party commentary is supportive financial media (Zhitong Finance) on profit recovery and import substitution, which should not be treated as independent research.

Bull case

  1. Medical inflection is real. Medical revenue rose 301.5% to S$25.4m in 1H2026, the TTM group run-rate is S$65.8m, and ex-SBP losses are near zero. If 2H2026 matches 1H2026, FY2026 medical revenue could exceed S$50m and deliver a first operating profit once share-based payments taper after April 2027.

  2. Medtronic validation plus a war chest. The co-launched navigated spinal endoscopy technique and framework agreement, together with about HK$82m of M&A proceeds, could produce an acquisition that adds proprietary products and higher margins.

  3. Simplification optionality. A sale or wind-down of Singapore manpower and dormitories could release capital (dormitory book value S$18.2m), remove a shrinking, policy-exposed segment and leave a pure-play medical story.

Bear case

  1. Concentration and quality of revenue. Two customers supplied 98% of 1H2026 product revenue, implied product margins are about 12–15%, and receivables and supplier credit have ballooned. That profile resembles low-value trading more than a defensible device franchise.

  2. Valuation detached from fundamentals. About 56x EV/sales and 71x P/B for a company with S$52m of equity and a record of losses, a 2021 SFC concentration warning, and an 8.4% overhang of deep-in-the-money options plus a 20% issue mandate leave substantial downside risk.

  3. Governance and related-party risk. The controlling shareholder holds about 47.7%. A new subsidiary is 49% owned by the Co-chairman's children, the group borrows from its parent, five directors have left since January 2025, and the CPA-qualified INED resigned in September 2026.

Catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhat to watch
FY2026 annual resultsApprox. late March 2027Medical revenue above S$50m? Gross margin above 20%? Operating cash flow positive?
Deployment of Aug 2025 proceedsBy Dec 2026Identity, price and related-party nature of any healthcare acquisition
Singapore business review2H2026Disposal, closure or restructuring of manpower and dormitories
Customer A and B disclosuresEach results releaseWhether concentration eases and new customers emerge
Medtronic collaborationOngoingDefinitive commercial agreements, procedure volumes, NMPA registrations
Option vesting and exerciseThird tranche 30 Apr 2027Dilution and selling pressure; SBP charge roll-off
Board compositionOngoingAudit committee accounting expertise after Ms. Yang's exit; further turnover
Working capitalInterim and annualReceivable days, payables over 90 days, parent-company loans
Use of issue mandateOngoingFurther discounted placements

Concluding analyst verdict

Jinhai Medical Technology is two very different companies inside one listed shell. One is a declining Singapore labour and dormitory operator whose revenue has fallen to S$16m and which management itself expects to be hurt by Singapore's AI-centric fiscal priorities. The other is a fast-growing Shanghai medical-products business, now three-quarters of revenue, that delivered S$25.4m of sales in the first half of 2026 alone and pulled group losses to near break-even before non-cash option costs. The Medtronic collaboration in navigated spinal endoscopy is the most credible piece of external validation the group has produced. Fresh insider capital provides runway, and the group holds about S$29m in cash and deposits against S$14m of secured debt.

The evidence does not yet support the thesis that Jinhai has built a defensible medical-technology franchise. Disclosed R&D is below 2% of revenue. Implied product margins sit in the low teens. Almost all product revenue comes from two undisclosed customers. Working capital is being financed by stretched supplier credit and parent loans. Governance is dominated by the controlling shareholder and a new co-chairman whose family co-owns the newest operating subsidiary. Board turnover has been unusually high.

Against these fundamentals, a market value of roughly HK$22.5 billion, about 56 times trailing sales and over 70 times book, prices in an outcome far beyond anything the filings demonstrate. Historical episodes of extreme shareholding concentration and the large overhang of deep-in-the-money options and issuance mandates add technical risk.

The verdict is that operating momentum is improving and genuine, but the investment case is speculative and valuation-driven. Institutional investors should treat the stock as high-risk. Re-underwriting should be conditional on three things: diversification of the customer base, disclosure of proprietary products and registrations, and the terms of the forthcoming healthcare acquisition funded by the August 2025 proceeds.


APPENDIX: SOURCES

Primary filings (HKEX):

Aggregators and media (flagged where used):

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointedAge (AR2025)Prior roles / backgroundEducation

Chen Guobao (陳國寶)

Chairman, Executive Director, Chair of Nomination Committee; controlling shareholder

19 Jul 2019

51

About 20 years in real estate and construction. Founded Shanghai Jinhai Corporate Development Group (2002; real estate development and property management incl. dormitories). Chairman of Shanghai Guobao Property (since 2006) and Shanghai Laiyada Property Development (since 2011). Executive deputy chairman, Ningbo Chamber of Commerce in Shanghai. Former NED of Vision Fame International (1315.HK), 2015–2017

Undergraduate studies in economic management, PLA Nanjing Artillery Academy (completed 2012)

Li Bin (李斌)

Co-chairman, Executive Director

3 Feb 2026

53

Founder and chairman of Shanghai Anbaida Investment Management Consulting (IVD reagent sales) since 2005; first-tier Roche Diagnostics distributor in Shanghai since 2004; senior management consultant to Jin Hai Holdings (HK) (Chen-owned), Sep 2025–Feb 2026

—

Wang Zhenfei (王振飛)

Chief Executive Officer, Executive Director, Remuneration Committee member

19 Jul 2019

45

Huaxia Bank Shanghai Branch, 2007–2015; CEO of Shanghai Jinhai Corporate Development Group since 2015

Business management (online distance learning), Southwest University of Science and Technology, 2007

Wang Huasheng (王華生)

Non-executive Director, Audit Committee member

19 Jul 2019

60

Founder and chairman of Shaanxi Yide Industrial (2004), Shaanxi Northwest Light Industry Wholesale Market Management (2006), Shanghai Gexin Investment (2007) and Shanghai Gexin Real Estate (2009)

—

Yan Jianjun (嚴健軍)

INED; Chair of Audit and Remuneration Committees; Nomination Committee member

19 Jul 2019

60

Chairman, Shanghai Zhida Technology Group (since 1999). Independent director of Dazhong Transportation (600611.SS) since 2024; INED of Butong Group (6090.HK) since Sep 2025; formerly independent director of Shanghai Lonyer Fuels (603003.SH). Shanghai People's Congress deputy; National Model Worker

BEng (electrical engineering), Shanghai University of Engineering Science; EMBA, CEIBS (2003)

Fan Yimin (范一民)

INED; Audit, Remuneration and Nomination Committee member

19 Jul 2019

43

Bank of China Shanghai (2005–2012); Shanghai Stem Cell Technology (2012–2015); Shanghai Zhengming Modern Logistics (2016–2017); KEB Hana Bank (China) Shanghai, assistant GM, corporate division (since 2018)

Bachelor's in finance, Donghua University (2005)

Liu Jinjing (劉金晶)

INED; Audit and Nomination Committee member

18 Sep 2026

———

“—” = not publicly disclosed.

Executive Leadership Team

NameRoleSinceNotes

Wang Zhenfei

CEO

Jul 2019

See above; holds 25.85m options at HK$0.635 (post-subdivision)

Liu Lei (劉鐳)

Chief Technical Officer; director and GM of Shanghai Jinhai Medical

—

Largest option holder: 284.35m options outstanding at 30 Jun 2026, about 5.4% of issued shares

Wong Man Yiu (黃文耀)

CFO (rejoined 1 Sep 2025); Company Secretary and Authorised Representative (29 Sep 2025)

2025 (previously 2019–2023)

Aged 58; HKICPA associate (1996), ACCA fellow (2001)

Ma Chengdong (馬成棟)

Chief Marketing Officer

3 Aug 2026 (initial 1-year term)

Oversees marketing, market access, academic promotion, sales and channels for medical devices

“—” = not publicly disclosed.

Executive Leadership Team by Person

PersonComponentAmountSource

Li Bin

Fixed director's fee

HK$200,000 per month (HK$2.4m annualised); 3-year service contract

Appointment announcement, 3 Feb 2026

Jiang Jiangyu (former)

Director's fee

HK$504,000 per annum

Appointment announcement, 28 Jan 2025

Senior management (per AR2025 band table)

Total remuneration

2 individuals HK$500,001–1,500,000; 2 individuals HK$3,500,001–4,000,000

AR2025 CG Report

Individual directors' salary/bonus/share-based totals

FY2025

—

AR2025

Group staff costs incl. directors

FY2025

S$22.5m (incl. S$9.1m share-based payments); FY2024 S$30.5m

FY2025 results

Major Shareholders

HolderShares% of issued sharesDate / source

Full Fortune International Co., Ltd (100% Chen Guobao; spouse Jiang Xiahong deemed interested)

2,530,000,000

47.82 (approx. 47.74 on 5,299m shares at 30 Jun 2026)

AR2025 (31 Dec 2025)

Li Bin (Co-chairman)

40,000,000

approx. 0.75

Appointment announcement, Feb 2026

Li Yue and Li Zekai (Li Bin's children), combined

—

approx. 1.51

Derived from 120m August 2025 subscription

Option holders (Liu Lei 284.35m; Wang Zhenfei 25.85m; four employees 135.76m)

445,960,000 options outstanding

approx. 8.4 potential dilution

1H2026 results

Institutional investors (top 10)

Not publicly disclosed (none above the 5% SFO threshold reported)

—

AR2025 Section 336 register

Public float

Approx. 50% by arithmetic; the company confirmed sufficient public float throughout FY2025 and 1H2026

—

Results announcements

Competitive Landscape

Key Competitors

CompetitorListingRelevanceRelative positioning vs Jinhai

Medtronic plc

NYSE: MDT

Global leader in spine, navigation and neurosurgery; Jinhai's partner in navigated spinal endoscopy

Orders of magnitude larger (FY ended April 2025 revenue approx. US$33.5bn); simultaneously partner and potential competitor

Johnson & Johnson MedTech (DePuy Synthes)

NYSE: JNJ

Spine, orthopaedics and endoscopy

Global scale; competes in hospital spine procurement

Stryker

NYSE: SYK

Spine, navigation and endoscopy

Global scale

Olympus

TSE: 7733

Endoscopy systems

Global leader in visualisation

Karl Storz

Private

Endoscopy and MIS visualisation

Global leader; private

MicroPort Scientific

HKEX: 0853

Diversified Chinese device maker incl. orthopaedics

Far larger, vertically integrated

MicroPort MedBot

HKEX: 2252

Surgical robotics incl. orthopaedic and endoscopic robots

R&D-intensive robotics platform

Kangji Medical

HKEX: 9997

Chinese MIS instruments (laparoscopic)

Profitable domestic MIS specialist

Shandong Weigao Group Medical Polymer

HKEX: 1066

Broad consumables incl. orthopaedics

Large, diversified

Shanghai Sanyou Medical

SSE: 688085

Domestic spine implants

Spine specialist

Weigao Orthopaedic

SSE: 688161

Domestic orthopaedic and spine implants

Spine specialist

Joimax

Private (Germany)

Spinal endoscopy and navigation systems

Niche global spinal endoscopy specialist

Key Competitors — Centurion Corporation

CompetitorListingRelevance

Centurion Corporation

SGX: OU8

Purpose-built workers' accommodation operator in Singapore and Malaysia

Numerous private foreign-worker agencies and labour suppliers

Private

Fragmented, licence-based Singapore manpower supply

Peer Comparison FY2025

MetricJinhai (FY2025)Medtronic

Revenue

S$46.3m group; S$30.0m medical

Approx. US$33.5bn (FY Apr 2025)

Revenue growth

−7.9% group; +15.6% medical; +301.5% medical in 1H2026

—

Gross margin

15.5% group; approx. 12.7% implied on products

—

Operating margin

−35.6% (EBIT)

—

R&D intensity

1.6% of revenue

—

Business model

Distributor and solution provider with concentrated customers

Global OEM

Recent Developments

Headcount declined modestly from 488 to 472 between end-2024 and mid-2026.

Company Snapshot

$35.3M

Revenue

472

Employees

$2,900M

Market Cap

2006

Founded

Singapore

Headquarters

SWOT Analysis

Strengths

  • Rapid medical scaling. Medical revenue grew from S$0.66m (FY2022) to S$29.96m (FY2025) and S$25.43m in 1H2026 (+301.5% YoY) (FY2022, FY2025 and 1H2026 results).
  • Liquidity. Cash and time deposits were S$28.7m against borrowings and leases of S$14.2m at 30 June 2026; gearing was 25.5% (1H2026 results).
  • Committed insider capital. HK$100m raised in October 2023 and HK$162m in August 2025 at prices of HK$1.60 (pre-split) and HK$1.35.
  • Medtronic partnership. Co-launch of navigated spinal endoscopy at CIIE in November 2025, plus a framework agreement with Medtronic Changzhou on 6 November 2025 (AR2025).
  • Improving loss trajectory. The 1H2026 loss narrowed to S$3.6m from S$10.8m, and gross margin improved from 14.3% to 19.5% (1H2026 results).
  • Tangible collateral. Singapore investment properties carried at S$18.2m support secured borrowing capacity (1H2026 results).

Weaknesses

  • Customer concentration. Customers A and B accounted for 73.6% of group revenue in 1H2026; Customer B alone was 48.2% of FY2024 revenue (FY2025 and 1H2026 results).
  • Low product margins. Implied product margin was about 4.5% in FY2024 and about 12.7% in FY2025, based on cost of inventories sold (analyst calculation from FY2025 results).
  • Negligible R&D. S$742k (1.6% of revenue) in FY2025 and S$112k in 1H2026, while HK$32.2m of R&D proceeds remained unused (FY2025 and 1H2026 results).
  • Persistent losses. Losses attributable to owners were S$3.1m (FY2023), S$18.0m (FY2024) and S$17.1m (FY2025); accumulated losses were S$46.6m at the company level (AR2025).
  • Working-capital strain. Receivable days rose to about 121 and payables over 90 days to S$8.0m at mid-2026 (FY2025 and 1H2026 results).
  • Disclosure and control history. The FY2021 restatement for GST errors dates back to 2014 (FY2022 results, Note 2.1). Product-level disclosure is minimal.

Opportunities

  • Market tailwind. China's MIS-device market is forecast to grow at a 9.45% CAGR to US$2.68bn by 2030 (Mordor, cited in AR2025).
  • M&A firepower. HK$81.9m of M&A proceeds was unutilised at 30 June 2026 and targeted for deployment by December 2026 (1H2026 results).
  • IVD and distribution adjacency. The Co-chairman's Roche IVD distribution background and the Jinhai Biomedical platform could broaden the portfolio (AR2025 biography).
  • Navigation and robotics trend. Management cites robotics, AI imaging and minimally traumatic tools as key drivers (AR2025 MD&A).
  • Singapore exit or monetisation. The planned 2H2026 review could release capital from dormitories (S$18.2m carrying value) and simplify the equity story (1H2026 MD&A).
  • Operating leverage. Ex-SBP, 1H2026 was near break-even (approx. S$0.4m loss). Further revenue growth on a fixed admin base could deliver profitability (analyst calculation).

Threats

  • Customer loss. Losing either key customer would cut revenue dramatically, as the 1H2025 product revenue drop of 48.5% illustrated.
  • VBP pricing. National and provincial VBP for spine and orthopaedic consumables compresses pricing.
  • Partner substitution. Medtronic or other OEMs could choose different partners; the framework terms are undisclosed (AR2025).
  • Singapore structural decline. Singapore revenue fell 33% in FY2025, and management expects material impact from the AI Budget (FY2025 MD&A).
  • Dilution. 445.96m options at HK$0.635 (about 8.4%) are deep in the money, and the AGM granted a 20% issue mandate (about 1.06bn shares) (1H2026 results; AGM circular).
  • Valuation and liquidity risk. A market cap of about HK$22.5bn against TTM revenue of S$65.8m (about 56x EV/sales), plus an SFC concentration warning precedent (2021), implies scope for sharp de-rating.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025First option tranche (20%) vesting date (30 Apr 2025), subject to FY2024 performance targetsOpens dilution and exercise window
Jun 2025AGM held 25 June 2025 in Shanghai; auditor re-appointed; issue mandateRoutine; mandate later used for August subscription
11 Jul 2025Subscription agreements: 120m shares at HK$1.35 (17.68% discount to HK$1.64 close)Brings in the Li family as strategic investors
15 Aug 2025Subscription completed; gross HK$162m, net approx. HK$161mCash rises to S$35.6m by year-end
26 Aug 2025Profit warning for 1H2025 (loss approx. S$10.8m vs S$6.0m)Signals medical sales slump in 1H2025
29 Aug 20251H2025 results: revenue −44% to S$14.5m; gross margin 14.3%; gearing 52.8%Low point of the cycle
1 Sep 2025Wong Man Yiu rejoins as CFORestores experienced finance leadership
23 Sep 20252025 Interim Report publishedFiling
29 Sep 2025Change of Company Secretary (Cheng Yuen out, Wong Man Yiu in)Governance
15 Oct 2025Voluntary announcement on co-launch of spinal endoscopy technique with Medtronic ChinaFirst major technology partnership disclosure
Nov 2025Joint launch at the 8th CIIE, ShanghaiBrand visibility
6 Nov 2025Strategic cooperation framework with Medtronic ChangzhouDeepens Medtronic relationship
18 Nov 2025Change of Hong Kong principal place of business (to Wan Chai)Administrative
23 Jan 2026Jinhai Biomedical established (51/49 with Li family vehicle)New growth vehicle; related-party structure
29 Jan 2026NED and Vice-chairman Jiang Jiangyu resignsBoard turnover
3 Feb 2026Li Bin appointed ED and Co-chairman (HK$2.4m p.a. fee)Second power centre on the board
12 Feb 2026Singapore FY2026 Budget launches national AI MissionsManagement flags material adverse impact on Singapore construction-linked businesses
25 Feb 2026Connected transaction: Jinhai Biomedical capital increase to RMB25mScale-up of new JV
27 Mar 2026FY2025 results: revenue S$46.3m (−7.9%), loss S$17.4m; medical +15.6%Medical now 65% of revenue
24 Apr 20262025 Annual Report publishedFiling
30 Apr 2026Second option tranche (30%) vesting dateDilution
12 May 2026AGM circular: 20% issue mandate (about 1.06bn shares), 10% buyback mandate (about 529m shares)Large dilution capacity
13 May 20269m options exercised at HK$0.635First option exercise
15 Jun 2026AGM; poll results announcedMandates refreshed
3 Aug 2026Ma Chengdong appointed Chief Marketing OfficerCommercial build-out
27 Aug 20261H2026 results: revenue +134.2% to S$34.0m; medical +301.5%; loss narrows to S$3.6mStrongest half on record; near break-even ex-SBP
Late Aug 2026Zhitong Finance commentary highlights profit recovery and import-substitution thesisSupportive sell-side-style media; not independent research
14 Sep 2026Supplemental announcement to 2025 Annual Report (use of proceeds and share option scheme updates)Disclosure clean-up
16 Sep 20262026 Interim Report publishedFiling
18 Sep 2026Li Yunping (ED) and Yang Meihua (INED) resign; Liu Jinjing appointed INEDLoss of CPA-qualified INED and audit committee member
2 Oct 2026Monthly return for September 2026Share-capital tracking

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from SGD 21.9 Mn in FY2021 to SGD 46.3 Mn in FY2025.
Jinhai Medical Technology Limited — Income Statement: Revenue & Gross Profit
Series (SGD Mn)FY2021FY2022FY2023FY2024FY2025
Revenue21.922.345.650.246.3
Cost of sales and services14.212.233.638.839.1
Gross profit7.710.11211.57.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.